Rectum

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Retrieved on: 
Monday, March 4, 2024

“This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.

Key Points: 
  • “This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.
  • The Focal One system being granted a Breakthrough Device designation underscores the significance of this innovative development for DIE patients.
  • In January 2022, EDAP reported positive results from the Phase 2 Endo-HIFU-1R study (N=60) evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis, and this data was included in EDAP’s submission in consideration for receiving Breakthrough Device designation from the FDA.
  • In February 2024, EDAP announced the completion of enrollment in a Phase 3 study evaluating Focal One HIFU therapy for the treatment of deep infiltrating rectal endometriosis.

NY Cancer Survivor Offers Blueprint for Patient Empowerment

Retrieved on: 
Wednesday, March 6, 2024

SOMERSET, N.J., March 6, 2024 /PRNewswire/ -- Walter Krysevig, a 77-year-old cancer survivor from Somers, NY, embodies the transformative power of patient empowerment in navigating complex medical decisions.

Key Points: 
  • SOMERSET, N.J., March 6, 2024 /PRNewswire/ -- Walter Krysevig, a 77-year-old cancer survivor from Somers, NY, embodies the transformative power of patient empowerment in navigating complex medical decisions.
  • His proactive approach not only reshaped his treatment journey but also serves as a blueprint for others facing similar challenges.
  • Faced with a diagnosis of Stage 4 prostate cancer, Krysevig refused to accept a passive role in his care.
  • As Krysevig celebrates a major milestone of five years post-diagnosis, his story shows that patient empowerment can lead to positive outcomes.

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.

Colorectal cancer is the 2nd deadliest cancer in Canada, let's work together to avoid making it number one

Retrieved on: 
Monday, February 26, 2024

Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.

Key Points: 
  • Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.
  • Despite being preventable and highly treatable when detected early, the reluctance to participate in colorectal cancer screening has hindered early detection efforts.
  • This alarming reality serves as a stark reminder that vigilance and advocacy are paramount in the fight against colorectal cancer.
  • Join Colorectal Cancer Canada in our mission to save lives, break barriers, and promote equitable access to colorectal cancer resources across Canada.

Lancet Digital Health Study Confirms MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Retrieved on: 
Thursday, February 22, 2024

HAIFA, Israel, Feb. 22, 2024 /PRNewswire/ -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Key Points: 
  • The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category.
  • The study shows that using MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values.
  • In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
  • "We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research," said Dror Zur, Founder & CEO, MAGENTIQ EYE.

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

Retrieved on: 
Thursday, February 1, 2024

LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.

Key Points: 
  • LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.
  • The ongoing Phase 3 study ( NCT05755958 ) is a comparative, randomized, double blind trial, with the primary objective of evaluating acute pelvic pain levels in 60 patients.
  • In January 2022, EDAP reported positive results from the Phase 2 Endo-HIFU-1R study (N=60) evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis.
  • The study also evaluated the effect of HIFU treatment on endometriosis symptoms and Quality of Life (QoL).

City of Hope, TGen Researchers Develop Machine-Learning Tool to Detect Cancer Earlier via Liquid Biopsy

Retrieved on: 
Wednesday, January 24, 2024

(Photo Credit: TGen)

Key Points: 
  • (Photo Credit: TGen)
    “A huge body of evidence shows that cancer caught at later stages kills people.
  • The technology City of Hope, TGen and colleagues developed was able to identify half of the cancers in the 11 studied types.
  • Importantly, most of the cancer samples originated from people with early-stage disease, who had few or no metastatic lesions at diagnosis.
  • The prospective trial will determine the effectiveness of the biomarker panel in detecting an earlier stage of cancer when it is more treatable.

The Inner Circle Acknowledges, Hank C. Hill as a Pinnacle Life Member

Retrieved on: 
Monday, January 29, 2024

BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.

Key Points: 
  • BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.
  • Dr. Hill pursued higher education at the Brooklyn Campus of Long Island University where he earned his Bachelor of Science degree in Biology/Pre-Med.
  • Anderson Cancer Center in Houston, where he earned a surgical oncology research fellowship certificate in tumor biology.
  • Aside from his professional pursuits, Dr. Hill enjoys traveling, dancing (soca, reggae, reggaeton, R&B), and listening to music.